Search Results - "Desai, Sanjal H"

Management of post‐transplant lymphoproliferative disorders by DeStefano, Christin B., Desai, Sanjal H., Shenoy, Aarthi G., Catlett, Joseph P.

“…Summary The post‐transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of neoplasms that are one of the most serious complications of bone…”
Get full text

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study by Desai, Sanjal H., LaPlant, Betsy, Macon, William R., King, Rebecca L., Wang, Yucai, Inwards, David J., Micallef, Ivana, Johnston, Patrick B., Porrata, Luis F., Ansell, Stephen M., Habermann, Thomas M., Witzig, Thomas E., Nowakowski, Grzegorz S.

“…Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide…”
Get full text

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts by Desai, Sanjal H., Pederson, Levi, LaPlant, Betsy, Mwangi, Raphael, Maurer, Matthew, Young, Jason R., Macon, William R., King, Rebecca L., Wang, Yucai, Cerhan, James R., Feldman, Andrew, Inwards, David J., Micallef, Ivana, Johnston, Patrick, Porrata, Luis F., Ansell, Stephen M., Habermann, Thomas M., Witzig, Thomas E., Nowakowski, Grzegorz S.

“…Studies evaluating Positron Emission Tomography scan after 2 cycles of chemotherapy (PET2) in newly diagnosed diffuse large B cell lymphoma (DLBCL) are…”
Get full text

Lymphoma survivors have an increased long-term risk of chronic kidney disease by Desai, Sanjal H., Al-shbool, Ghassan, Desale, Sameer, Veis, Judith, Malkovska, Vera

“…With improving lymphoma survival, late effects of therapy have emerged. Here, we describe pattern of long-term chronic kidney disease (CKD) in lymphoma…”
Get full text

Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma by Desai, Sanjal H., Spinner, Michael A., David, Kevin, Bachanova, Veronika, Goyal, Gaurav, Kahl, Brad, Dorritie, Kathleen, Azzi, Jacques, Kenkre, Vaishalee P., Arai, Sally, Chang, Cheryl, Fusco, Brendon, Sumransub, Nuttavut, Hatic, Haris, Saba, Raya, Ibrahim, Uroosa, Harris, Elyse I., Shah, Harsh, Murphy, Jacob, Ansell, Stephen, Jagadish, Deepa, Orellana‐noia, Victor, Diefenbach, Catherine, Iyenger, Siddharth, Rappazzo, K. C., Mishra, Rahul, Choi, Yun, Nowakowski, Grzegorz S., Advani, Ranjana H., Micallef, Ivana N.

“…Clinical trials of novel salvage therapies have encouraging outcomes for relapsed/refractory transplant‐eligible classic Hodgkin lymphoma (R/R cHL) but…”
Get full text

Clearance of Hepatitis C Virus (HCV) Is Associated With Improved Outcomes in HCV-Associated Lymphoma by Desai, Sanjal H., Baez-Sosa, Valentina, Hameed, Rumaisa, Al-Shbool, Ghassan, Fernandez, Stephen, Vakiti, Anusha, Stingo, Facundo, Adhikari, Tripti, Paku, Emily, Malkovska, Vera, Fishbein, Dawn

“…Improved hepatitis C virus (HCV) clearance due to directly acting antiviral agents has led to remarkably improved outcomes of indolent HCV-associated…”
Get full text

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma by Desai, Sanjal H., Mwangi, Raphael, Smith, Alexandra N., Maurer, Matthew J., Farooq, Umar, King, Rebecca L., Cerhan, James R., Feldman, Andrew L., Habermann, Thomas M., Thompson, Carrie A., Wang, Yucai, Ansell, Stephen M., Witzig, Thomas E., Nowakowski, Grzegorz S.

“…Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to…”
Get full text

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era by Desai, Sanjal H., Spinner, Michael A, Evens, Andrew M., Sykorova, Alice, Bachanova, Veronika, Goyal, Gaurav, Kahl, Brad, Dorritie, Kathleen, Azzi, Jacues, Kenkre, Vaishali P., Chang, Cheryl, Michalka, Josef, Ansell, Stephen M., Fusco, Brendon, Sumransub, Nuttavut, Hatic, Haris, Saba, Raya, Ibrahim, Uroosa, Harris, Elyse I., Shah, Harsh, Wagner-Johnston, Nina, Arai, Sally, Nowakowski, Grzegorz S., Mockikova, Heidi, Jagadeesh, Deepa, Blum, Kristie A., Diefenbach, Catherine, Iyengar, Siddharth, Rapazzo, K. C., Baidoun, Firas, Choi, Yun, Prochazka, Vit, Advani, Ranjana H., Micallef, Ivana

“…•Overall survival of patients with cHL who progress after ASCT, approached 9.5 years in the novel agent era.•Patients who receive CPI as first treatment for…”
Get full text

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis by Desai, Sanjal H., Mwangi, Raphael, Ng, Wern Lynn, King, Rebecca L., Maurer, Matthew J., Cerhan, James R., Feldman, Andrew L., Farooq, Umar, Mou, Eric, Habermann, Thomas M., Thompson, Carrie A., Wang, Yucai, Witzig, Thomas E., Nowakowski, Grzegorz S.

“…•Patients who underwent core needle biopsy are more likely to have poor-risk disease features and inadequate tissue for molecular analyses.•Increasing tissue…”
Get full text

DA-EPOCH-R Has Comparable Outcomes in De Novo and Transformed Diffuse Large B Cell Lymphoma by Desai, Sanjal H, Chaturvedi, Mansi, Hameed, Rumaisa, Baez Sosa, Valentina, Shenoy, Aarthi

“…Introduction It is increasingly recognized that transformed (T) diffuse large B cell lymphoma (DLBCL) is a clinically and biologically distinct entity from de…”
Get full text

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies by Stuver, Robert, Drill, Esther, Ganesan, Nivetha, Baron, Kelsey, Casper, Ellie, Chang, Tiffany, Desai, Sanjal H., Falade, Ayo S, Galasso, Natasha, Herrera, Alex F., Mei, Matthew G., Merryman, Reid W., Micallef, Ivana, Shah, Harsh, Moskowitz, Alison

“…Background: For patients with relapsed and refractory (R/R) classical Hodgkin lymphoma (HL), the standard of care remains salvage therapy followed by…”
Get full text

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era by Desai, Sanjal H, Mwangi, Raphael, Wang, Yucai, Farooq, Umar, Mou, Eric, Feldman, Andrew L., Syrbu, Sergei, Slager, Susan L., Nowakowski, Grzegorz S., Maurer, Matthew J., Kay, Neil E., Habermann, Thomas M., Link, Brian K., Thompson, Carrie A., Cerhan, James R.

Get full text

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers by Voorhees, Timothy, McLaughlin, Eric, Torka, Pallawi, Florindez, Jorge A, Moyo, Tamara K., Reves, Heather, Sumransub, Nuttavut, Deshpande, Saarang, Rose, Ashley, Duarte, Cassandra, Faisal, Muhammad Salman, Hamid, Showkat, Subbiah, Suki, Ayyappan, Sabarish R., Shea, Lauren Kelly, Cortese, Matthew J, Patel, Krish, Major, Ajay, Saeed, Hayder, Svoboda, Jakub, Desai, Sanjal H., Ramakrishnan Geethakumari, Praveen, Grover, Natalie S., Epperla, Narendranath

“…Background: Brentuximab vedotin (BV) and anti-PD-1 therapies (nivolumab and pembrolizumab) have changed the therapeutic landscape for patients (pts) with…”
Get full text

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents by Falade, Ayo S, Redd, Robert A., Shah, Harsh, Baron, Kelsey, Iyengar, Siddharth, Desai, Sanjal H., Ansell, Stephen M, Micallef, Ivana, Nedved, Adrienne, Ganesan, Nivetha, Chang, Tiffany, Shah, Gunjan L., Stuver, Robert, Moskowitz, Alison, Mei, Matthew Genyeh, Othman, Tamer, Ong, Shin Yeu, Herrera, Alex F., Armand, Philippe, Merryman, Reid W.

“…Background: Maintenance therapy with brentuximab vedotin (BV) after autologous stem cell transplantation (ASCT) improved progression-free survival (PFS) among…”
Get full text

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort by Desai, Sanjal H., Merryman, Reid W., Shah, Harsh, Pederson, Levi D., Geyer, Susan M., Ganesan, Nivetha, Chang, Tiffany, Othman, Tamer, Falade, Ayo S, Shah, Gunjan L., Durani, Urshila, Baron, Kelsey, Ong, Shin Yeu, Ansell, Steve M, Armand, Philippe, Iyengar, Siddharth, Micallef, Ivana, Moskowitz, Alison, Herrera, Alex F., Stuver, Robert, Mei, Matthew Genyeh

“…Introduction: Single arm studies incorporating PD-1 blockade and/or brentuximab vedotin (BV) to salvage regimen have produced encouraging results in…”
Get full text

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers by Voorhees, Timothy, Grover, Natalie S., McLaughlin, Eric, Florindez, Jorge A, Moyo, Tamara K., Reves, Heather, Sumransub, Nuttavut, Deshpande, Saarang, Rose, Ashley, Duarte, Cassandra, Faisal, Muhammad Salman, Hamid, Showkat, Subbiah, Suki, Ayyappan, Sabarish R., Shea, Lauren Kelly, Cortese, Matthew J, Patel, Krish, Major, Ajay, Saeed, Hayder, Svoboda, Jakub, Desai, Sanjal H., Ramakrishnan Geethakumari, Praveen, Torka, Pallawi, Epperla, Narendranath

“…Background: Patients (pts) with classical Hodgkin Lymphoma (cHL) who become refractory to both BV and anti-PD-1 therapies (double refractory, DR) or intolerant…”
Get full text

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant by Baron, Kelsey, Drill, Esther, Ganesan, Nivetha, Merryman, Reid W., Mei, Matthew G., Stuver, Robert, Desai, Sanjal H., Falade, Ayo S, Iyengar, Siddharth, Micallef, Ivana, Ng, Lay She, Casper, Ellie, Galasso, Natasha, Tao, Randa, Dandapani, Savita, Ng, Andrea, Yahalom, Joachim, Herrera, Alex F., Moskowitz, Alison, Shah, Harsh

“…Introduction There is no prospective data to guide the utilization of peri-transplant radiation (PTRT) in patients with relapsed or refractory (R/R) classical…”
Get full text

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers by Annunzio, Kaitlin, McLaughlin, Eric, Voorhees, Timothy, Shea, Lauren Kelly, Sumransub, Nuttavut, Rose, Ashley, Olszewski, Adam J, Bailey, Neil, Patel, Krish, Moyo, Tamara K., Awan, Farrukh T., Ahmed, Gulrayz, Grover, Natalie S., Adika, Adam, Andres, Erica L, Faisal, Muhammad Salman, Christian, Beth, Anna, Jacob, Bair, Steven M., Kendsersky, Nicholas, Thomas, Colin, Torka, Pallawi, Svoboda, Jakub, Carter, Jordan S, Hamadani, Mehdi, Saeed, Hayder, Desai, Sanjal H., Evens, Andrew M, Epperla, Narendranath

“…Introduction The cornerstone for management of newly diagnosed patients (pts) with cHL is an anthracycline (AC) based chemotherapy (chemo) regimen. There are a…”
Get full text

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy by Desai, Sanjal H., Sumransub, Nuttavut, Evans, Rich, Watkins, Marcus P, Karmali, Reem, Goyal, Gaurav, Hughes, Mitchell E., Khurana, Arushi, Hernandez-Ilizaliturri, Francisco J., Zurko, Joanna, Hassan, Ayesha, Hatic, Haris, Nizamuddin, Imran A., Evens, Andrew M, Anampa-Guzmán, Andrea Carolina, Lin, Yi, Isufi, Iris, Hamadani, Mehdi, Rajguru, Saurabh A, Lall, Naveena, Tun, Aung M., Hill, Brian T., Stephens, Deborah M., Caimi, Paolo F., Ermann, Daniel A., Kahl, Brad S., Landsburg, Daniel J., Nowakowski, Grzegorz S.

“…Introduction: DH/THL also classified as high-grade B cell lymphomas (HGBCL) with MYC and BCL2 and/or BCL6 rearrangements have higher risk of progression after…”
Get full text

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort by Desai, Sanjal H, Watkins, Marcus P., Karmali, Reem, Goyal, Gaurav, Hughes, Mitchell, Khurana, Arushi, Hernandez-Ilizaliturri, Francisco, Sumransub, Nuttavut, Zurko, Joanna, Nizamuddin, Imran A., Hatic, Haris, Landsburg, Daniel A, Anampa-Guzman, Andrea, Hamadani, Mehdi, Lin, Yi, Isufi, Iris, Tun, Aung M, Hill, Brian T., Stephens, Deborah M., Caimi, Paolo F, Ermann, Daniel A., Kahl, Brad S., Nowakowski, Grzegorz S.

Get full text